120 related articles for article (PubMed ID: 10892664)
1. Effects of a new class III antiarrhythmic drug nibentan in a canine model of vagally mediated atrial fibrillation.
Fedorov VV; Sharifov OF; Beloshapko GG; Yushmanova AV; Rosenshtraukh LV
J Cardiovasc Pharmacol; 2000 Jul; 36(1):77-89. PubMed ID: 10892664
[TBL] [Abstract][Full Text] [Related]
2. [Antiarrhythmic Efficacy of a New Class III Antiarrhythmic Drug RG-2.].
Fedorov VV; Rozenshtraukh LV; Reznik AV; Beloshapko GG; Iushmanova AV; Golitsyn SP; Ruda MIa; Chazov EI
Kardiologiia; 2004; 44(11):66-73. PubMed ID: 15602444
[TBL] [Abstract][Full Text] [Related]
3. [Effect of the class III antiarrhythmic drug nibentan in vagotonic atrial fibrillation].
Popova EP; Lyskovtsev VV; Kaverina NV
Eksp Klin Farmakol; 2006; 69(1):24-7. PubMed ID: 16579055
[TBL] [Abstract][Full Text] [Related]
4. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide.
Wang J; Feng J; Nattel S
Circulation; 1994 Oct; 90(4):2032-40. PubMed ID: 7923691
[TBL] [Abstract][Full Text] [Related]
5. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness.
Wang J; Bourne GW; Wang Z; Villemaire C; Talajic M; Nattel S
Circulation; 1993 Sep; 88(3):1030-44. PubMed ID: 8353865
[TBL] [Abstract][Full Text] [Related]
6. [Comparative study of the electrophysiological properties of class iii medicinals (cardiocyclide, nibentan, sotalol) and evaluation of their efficacy in atrial fibrillation produced by auricular and vagal stimulation].
Kaverina NV; Lyskovtsev VV; Popova EP
Eksp Klin Farmakol; 2007; 70(1):11-6. PubMed ID: 17402585
[TBL] [Abstract][Full Text] [Related]
7. [The first original Russian class-III antiarrhythmic nibentan].
Glushkov RG; Golitsyn SP; Dorodnikova EV; Maĭkov EB; Mashkovskiĭ MD; Merkulova IN; Rozenshtraukh LV; Ruda MIa; Skachilova SIa; Chazov EI; Iuzhakov SD
Vestn Ross Akad Med Nauk; 1998; (11):38-41. PubMed ID: 9889704
[TBL] [Abstract][Full Text] [Related]
8. Effects of a novel class III antiarrhythmic agent, NIP-142, on canine atrial fibrillation and flutter.
Nagasawa H; Fujiki A; Fujikura N; Matsuda T; Yamashita T; Inoue H
Circ J; 2002 Feb; 66(2):185-91. PubMed ID: 11999646
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation.
Wang Z; Pagé P; Nattel S
Circ Res; 1992 Aug; 71(2):271-87. PubMed ID: 1628386
[TBL] [Abstract][Full Text] [Related]
10. Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: role of suppressant effect in conductivity.
Iwasa A; Okumura K; Tabuchi T; Tsuchiya T; Tsunoda R; Matsunaga T; Tayama S; Yasue H
Eur J Pharmacol; 1998 Aug; 356(1):31-40. PubMed ID: 9761421
[TBL] [Abstract][Full Text] [Related]
11. Ranolazine terminates atrial flutter and fibrillation in a canine model.
Bhimani AA; Yasuda T; Sadrpour SA; Khrestian CM; Lee S; Zeng D; Belardinelli L; Waldo AL
Heart Rhythm; 2014 Sep; 11(9):1592-9. PubMed ID: 25066042
[TBL] [Abstract][Full Text] [Related]
12. The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model.
Rossman EI; Liu K; Morgan GA; Swillo RE; Krueger JA; Gardell SJ; Butera J; Gruver M; Kantrowitz J; Feldman HS; Petersen JS; Haugan K; Hennan JK
J Pharmacol Exp Ther; 2009 Jun; 329(3):1127-33. PubMed ID: 19252062
[TBL] [Abstract][Full Text] [Related]
13. Different effects of class Ic and III antiarrhythmic drugs on vagotonic atrial fibrillation in the canine heart.
Hayashi H; Fujiki A; Tani M; Usui M; Inoue H
J Cardiovasc Pharmacol; 1998 Jan; 31(1):101-7. PubMed ID: 9456284
[TBL] [Abstract][Full Text] [Related]
14. Effects of E047/1, a new antiarrhythmic drug, on experimental atrial fibrillation in anesthetized dogs.
Sharifov OF; Fedorov VV; Beloshapko GG; Yushmanova AV; Rosenshtraukh LV
J Cardiovasc Pharmacol; 2001 Nov; 38(5):706-14. PubMed ID: 11602817
[TBL] [Abstract][Full Text] [Related]
15. Electrophysiologic Effects of the New Class III Antiarrhythmic Drug Dofetilide in an Experimental Canine Model of Pacing-induced Atrial Fibrillation.
Feld GK; Cha Y
J Cardiovasc Pharmacol Ther; 1997 Jul; 2(3):195-203. PubMed ID: 10684458
[TBL] [Abstract][Full Text] [Related]
16. Termination of Atrial Flutter and Fibrillation by K201's Metabolite M-II: Studies in the Canine Sterile Pericarditis Model.
Sadrpour SA; Serhal M; Khrestian CM; Lee S; Fields T; Dittrich HC; Waldo AL
J Cardiovasc Pharmacol; 2015 May; 65(5):494-9. PubMed ID: 25636078
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias.
Gautier P; Serre M; Cosnier-Pucheu S; Djandjighian L; Roccon A; Herbert JM; Nisato D
J Cardiovasc Pharmacol; 2005 Feb; 45(2):125-35. PubMed ID: 15654261
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiologic effects of a new class III antiarrhythmic agent, E-4031, on atrial flutter, atrial refractoriness, and conduction delay in a canine sterile pericarditis model.
Shimizu A; Kaibara M; Centurion OA; Kapuku G; Hirata T; Fukatani M; Yano K; Hashiba K
J Cardiovasc Pharmacol; 1993 Apr; 21(4):656-62. PubMed ID: 7681913
[TBL] [Abstract][Full Text] [Related]
19. Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation.
Li D; Bénardeau A; Nattel S
Circulation; 2000 Jul; 102(1):104-12. PubMed ID: 10880422
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates.
Comtois P; Sakabe M; Vigmond EJ; Munoz M; Texier A; Shiroshita-Takeshita A; Nattel S
Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1489-504. PubMed ID: 18676686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
